On July 6, 2021 Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, reported that Dr. Mark Erlander, chief executive officer of Cardiff Oncology, will participate in a fireside chat and virtual 1×1 investor meetings at the William Blair Biotech Focus Conference 2021 taking place virtually from July 14-15, 2021 (Press release, Cardiff Oncology, JUL 6, 2021, View Source [SID1234584650]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details on the fireside chat can be found below.
Date: Thursday, July 15, 2021
Time: 12:00 – 12:45 PM ET
Webcast Link:
View Source
A replay of the fireside chat will be available by visiting the "Events" section of the Cardiff Oncology website after its conclusion and will be archived on the Company website for 30 days.